Metabolic syndrome in older women

Cover Page


Cite item

Full Text

Abstract

This paper presents the current literature data on the pathogenesis of metabolic disorders in menopause. The association of metabolic syndrome with a high risk of coronary heart disease, hypertension, diabetes, and insulin resistance is of great medical and social importance. It emphasizes the need for early diagnosis of metabolic syndrome in older women and optimization of therapeutic and preventive measures. The article highlights the role of pathogenetic, multi-component therapy, including menopausal hormone one, in the treatment of metabolic disorders in menopause.

About the authors

Maria A. Shalina

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Author for correspondence.
Email: amarus@inbox.ru

MD, PhD, the Head of the Menopause and Women’s Health Center

Russian Federation, Saint Petersburg

References

  1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607. https://doi.org/10.2337/diab.37.12.1595.
  2. Aguilar M, Bhuket T, Torres S, et al. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015;313(19):1973-1974. https://doi.org/10.1001/jama.2015.4260.
  3. Lovre D, Lindsey SH, Mauvais-Jarvis F. Effect of menopausal hormone therapy on components of the metabolic syndrome. Ther Adv Cardiovasc Dis. 2016. https://doi.org/10.1177/1753944716649358.
  4. Pucci G, Alcidi R, Tap L, et al. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol Res. 2017;120:34-42. https://doi.org/10.1016/j.phrs.2017.03.008.
  5. Santilli F, D’Ardes D, Guagnano MT, Davi G. Metabolic syndrome: sex-related cardiovascular risk and therapeutic approach. Curr Med Chem. 2017;24(24):2602-2627. https://doi.org/10.2174/0929867324666170710121145.
  6. Milewicz A, Jedrzejuk D, Dunajska K, Lwow F. Waist circumference and serum adiponectin levels in obese and non-obese postmenopausal women. Maturitas. 2010;65(3):272-275. https://doi.org/10.1016/j.maturitas.2009.11.008.
  7. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol. 2009;11(5):341-355. https://doi.org/10.3109/09513599709152559.
  8. Sowers M, Zheng H, Tomey K, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab. 2007;92(3):895-901. https://doi.org/10.1210/jc.2006-1393.
  9. Hajian-Tilaki KO, Heidari B. Prevalence of obesity, central obesity and the associated factors in urban population aged 20-70 years, in the north of Iran: a population-based study and regression approach. Obes Rev. 2007;8(1):3-10. https://doi.org/10.1111/j.1467-789X.2006.00235.x.
  10. Sternfeld B, Wang H, Quesenberry CP, Jr., et al. Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Womenʼs Health Across the Nation. Am J Epidemiol. 2004;160(9):912-922. https://doi.org/10.1093/aje/kwh299.
  11. Fonken LK, Workman JL, Walton JC, et al. Light at night increases body mass by shifting the time of food intake. Proc Natl Acad Sci U S A. 2010;107(43):18664-18669. https://doi.org/10.1073/pnas.1008734107.
  12. Pan A, Lucas M, Sun Q, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. 2010;170(21). https://doi.org/10.1001/archinternmed.2010.356.
  13. Bongarzone S, Savickas V, Luzi F, Gee AD. Targeting the receptor for advanced glycation endproducts (RAGE): A medicinal chemistry perspective. J Med Chem. 2017;60(17):7213-7232. https://doi.org/10.1021/acs.jmedchem.7b00058.
  14. Gambacciani M, Ciaponi M, Cappagli B, et al. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas. 2001;39(2):125-132. https://doi.org/10.1016/s0378-5122(01)00194-3.
  15. Guthrie JR, Dennerstein L, Taffe JR, et al. The menopausal transition: a 9-year prospective population-based study. The Melbourne Womenʼs Midlife Health Project. Climacteric. 2010;7(4):375-389. https://doi.org/10.1080/13697130400012163.
  16. Poehlman ET, Tchernof A. Traversing the menopause. Coron Artery Dis. 1998;9(12):799-804. https://doi.org/10.1097/00019501-199809120-00004.
  17. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Menopause-related changes in body fat distribution. Ann N Y Acad Sci. 2006;904(1):502-506. https://doi.org/10.1111/j.1749-6632. 2000.tb06506.x.
  18. Беляков Н.А., Сеидова Г.Б., Чубриева С.Ю., Глухов Н.Ю. Метаболический синдром у женщин. — СПб., 2005. — 440 с. [Belyakov NA, Seidova GB, Chubrieva SY, Glukhov NY. Metabolicheskiy sindrom u zhenshchin. Saint Petersburg; 2005. 440 p. (In Russ.)]
  19. Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang Y-F. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke. 2001;32(5):1104-1111. https://doi.org/10.1161/01.str.32.5.1104.
  20. Rossi R, Origliani G, Modena MG. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care. 2004;27(3):645-649. https://doi.org/10.2337/diacare.27.3.645.
  21. Peterlik M, Boonen S, Cross HS, Lamberg-Allardt C. Vitamin D and calcium insufficiency-related chronic diseases: an emerging world-wide public health problem. Int J Environ Res Public Health. 2009;6(10):2585-2607. https://doi.org/10.3390/ijerph6102585.
  22. Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009;361(12):1152-1163. https://doi.org/10.1056/NEJMoa0804381.
  23. Brand JS, van der Schouw YT, Onland-Moret NC, et al. Age at menopause, reproductive life span, and type 2 diabetes risk: results from the EPIC-InterAct study. Diabetes Care. 2013;36(4):1012-1019. https://doi.org/10.2337/dc12-1020.
  24. Baber RJ, Panay N, Fenton A, Group IMSW. 2016 IMS Recommendations on womenʼs midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. https://doi.org/10.3109/13697137.2015.1129166.
  25. Feigelson HS. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2004;13(2):220-224. https://doi.org/10.1158/1055-9965.epi-03-0301.
  26. Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst. 2015;107(2). https://doi.org/10.1093/jnci/djv088.
  27. Мишарина Е.В., Абашова Е.И., Потин В.В. Ожирение и репродуктивная функция женщины // Журнал акушерства и женских болезней. — 2016. — Т. 65. — № 5. — С. 64–74. [Misharina EV, Abashova EI, Potin VV. Obesity and ovarian insufficiency. Journal of obstetrics and women’s diseases. 2016;65(5):64-74. (In Russ.)]. https://doi.org/10.17816/JOWD65564-74.
  28. Подзолкова Н.М., Колода Ю.А., Подзолков А.В. Терапия бесплодия у пациенток с ожирением: современный взгляд на проблему // Проблемы репродукции. — 2012. — Т. 18. — № 3. — С. 37–41. [Podzolkova NM, Koloda YA, Podzolkov AV. INFertility Therapy in obese patients: modern trends. Modern reproductive technologies. 2012;18(3):37-41. (In Russ.)]
  29. Dag ZO, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc. 2015;16(2):111-117. https://doi.org/10.5152/jtgga.2015.15232.
  30. Чазова И.Е., Мычка В.Б. Метаболический синдром. — М., 2004. — 168 с. [Chazova IE, Mychka VB. Metabolicheskiy sindrom. Moscow; 2004. 168 p. (In Russ.)]
  31. Howard BV, Kuller L, Langer R, et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Womenʼs Health Initiative Observational Study. Circulation. 2005;111(12):1462-1470. https://doi.org/10.1161/01.CIR.0000159344.21672.FD.
  32. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29-322. https://doi.org/10.1161/CIR.0000000000000152.
  33. Ben Ali S, Belfki-Benali H, Aounallah-Skhiri H, et al. Menopause and metabolic syndrome in tunisian women. Biomed Res Int. 2014;2014:457131. https://doi.org/10.1155/2014/457131.
  34. Meirelles RMR. Menopausa e síndrome metabólica. Arq Bras Endocrinol Metabol. 2014;58(2):91-96. (In Spanish). https://doi.org/10.1590/0004-2730000002909.
  35. Reckelhoff JF. Basic research into the mechanisms responsible for postmenopausal hypertension. Int J Clin Pract. 2004;58(S139):13-19.
  36. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women. Hypertension. 2000;36(5):780-789. https://doi.org/10.1161/ 01.hyp.36.5.780.
  37. Hajian-Tilaki K, Heidari B. Comparison of abdominal obesity measures in predicting of 10-year cardiovascular risk in an Iranian adult population using ACC/AHA risk model: A population based cross sectional study. Diabetes Metab Syndr. 2018;12(6):991-997. https://doi.org/10.1016/j.dsx.2018.06.012.
  38. Lambrinoudaki I. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas. 2011;68(1):13-16. https://doi.org/10.1016/j.maturitas.2010.09.005.
  39. Amsterdam EA-SrPCWG. Consensus on womenʼs health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27(1):14-24. https://doi.org/10.1093/humrep/der396.
  40. Овсянникова Т.В. Инновационная терапия климактерических расстройств в постменопаузе // Журнал Российского общества акушеров-гинекологов. — 2009. — № 2. — С. 3–5. [Ovsyannikova TV. Innovatsionnaya terapiya klimaktericheskikh rasstroystv v postmenopauze. Zhurnal Rossiyskogo obshchestva akusherov-ginekologov. 2009;(2):3-5. (In Russ.)]
  41. Подзолков В.И., Никитина Т.И., Подзолкова Н.М., Брагина А.Е. Гистерэктомия как звено сердечно-сосудистого континуума // Кардиоваскулярная терапия и профилактика. — 2010. — № 3. — С. 73–79. [Podzolkov VI, Nikitina TI, Podzolkova NM, Bragina AE. Hysterectomy as a part of cardiovascular continuum. Cardiovascular therapy and prevention. 2010;(3):73-79. (In Russ.)]
  42. Коваленко Л.В., Белоцерковцева Л.Д., Корнеева Е.В. Патогенетическое обоснование терапии метаболических нарушений у женщин на фоне дефицита эстрогенов // Лечащий врач. — 2011. — № 7. — С. 56. [Kovalenko LV, Belotserkovtseva LD, Korneeva EV. Patogeneticheskoe obosnovanie terapii metabolicheskikh narusheniy u zhenshchin na fone defitsita estrogenov. Practitioner. 2011;(7):56. (In Russ.)]
  43. Writing Group on behalf of Workshop Consensus G. Aging, menopause, cardiovascular disease and HRT. International Menopause Society Consensus Statement. Climacteric. 2009;12(5):368-377. https://doi.org/10.1080/13697130903195606.
  44. Scheen AJ. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract. 2017;127:224-237. https://doi.org/10.1016/j.diabres.2017.03.009.
  45. Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849-870. https://doi.org/10.1161/CIRCULATIONAHA.117.028136.
  46. Altabas V. Drug treatment of metabolic syndrome. Curr Clin Pharmacol. 2013;8(3):224-231. https://doi.org/10.2174/1574884711308030009.
  47. Сметник В.П., Кулаков В.И. Руководство по климактерию. — М.: МИА, 2001. [Smetnik VP, Kulakov VI. Rukovodstvo po klimakteriyu. Moscow: MIA; 2001. (In Russ.)]
  48. Ettinger B. Effect of the Womenʼs Health Initiative on womenʼs decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol. 2003;102(6):1225-1232. https://doi.org/10.1016/j.obstetgynecol.2003.08.007.
  49. Davis SR, Castelo-Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric. 2012;15(5):419-429. https://doi.org/10.3109/13697137.2012.707385.
  50. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012;15(3):217-228. https://doi.org/10.3109/13697137.2012.656401.
  51. Oliver-Williams C, Glisic M, Shahzad S, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update. 2019;25(2):257-271. https://doi.org/10.1093/humupd/dmy039.
  52. Мохорт Т.В. Менопаузальный метаболический синдром: обоснование и возможности коррекции // Репродуктивное здоровье. Восточная Европа. — 2011. — № 2. — С. 123–133. [Mokhort TV. Menopauzal’nyiy metabolicheskiiy sindrom: obosnovanie i vozmozhnosti korrektsii. Reproductive health. Eastern Europe. 2011;(2):123-133. (In Russ.)]
  53. Hulley S. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280(7):605. https://doi.org/10.1001/jama.280.7.605.
  54. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med. 2006;21(4):363-366. https://doi.org/10.1111/j.1525-1497.2006.00389.x.
  55. Kriplani A, Periyasamy AJ, Agarwal N, et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception. 2010;82(2):139-146. https://doi.org/10.1016/j.contraception.2010.02.009.
  56. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Womenʼs Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. https://doi.org/10.1001/jama.2013.278040.
  57. Tan J. Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne. Int J Women Health. 2009:213. https://doi.org/10.2147/ijwh.s3916.
  58. Gaspard U, Endrikat J, Desager JP, et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception. 2004;69(4):271-278. https://doi.org/10.1016/j.contraception.2003.11.003.
  59. Геворкян М.А., Манухин И.Б., Юрковец М.Г. Гормональная контрацепция: консультирование в выборе методов и режимов предохранения от нежелательной беременности // Вопросы гинекологии, акушерства и перинатологии. — 2011. — Т. 10. — № 1. — С. 83–86. [Gevorkyan MA, Manukhin IB, Yurkovets MG. Hormonal contraception: counseling in choosing methods and regimens of preventing undesirable pregnancy. Problems of gynecology, obstetrics, and perinatology. 2011;10(1):83-86. (In Russ.)]
  60. Cuyas E, Martin-Castillo B, Bosch-Barrera J, Menendez JA. Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab. Cell Cycle. 2017;16(11):1022-1028. https://doi.org/10.1080/15384101.2017.1310353.
  61. Scheen AJ, Philips JC, Kridelka F. Role of metformin in gynaecology and obstetrics. Rev Med Liege. 2018;73(12):597-602.

Copyright (c) 2019 Shalina M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies